Literature DB >> 27349281

RIP kinase-mediated ROS production triggers XAF1 expression through activation of TAp73 in casticin-treated bladder cancer cells.

Yoon Hee Chung1, Daejin Kim2.   

Abstract

The p53 family protein p73 plays an important role in apoptosis induced by chemotherapeutic drugs. Transcriptionally active (TA) p73 (TAp73) substitutes for p53 in the response to stress. XIAP associated factor 1 (XAF1) is a novel predictive and prognostic factor in patients with bladder cancer, but the association between TAp73 and XAF1 expression in bladder cancer cells is poorly understood. Here, we investigated the status of TAp73 and XAF1 in T24 bladder cancer cells to identify molecular mechanisms in casticin‑exposed T24 cells. Casticin induced activation of JNK/p38 MAPK that preceded activation of the caspase cascade and disruption of the mitochondria membrane potential (∆ψm). Expression of XAF1 and TAp73 was also upregulated in casticin-treated T24 cells. Casticin treatment of T24 cells induced receptor-interacting protein (RIP) kinase expression and increased intracellular production of reactive oxygen species (ROS). Casticin-mediated ROS induced an increase in phosphorylated JNK/p38 MAPK, resulting in progressive upregulation of TAp73, which in turn led to XAF1 expression. Our data suggest that the apoptotic activity of casticin in T24 cells is mediated by activation of the TAp73-XAF1 signaling pathway through RIP kinase-mediated ROS production.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27349281     DOI: 10.3892/or.2016.4895

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

1.  Casticin inhibits esophageal cancer cell proliferation and promotes apoptosis by regulating mitochondrial apoptotic and JNK signaling pathways.

Authors:  Zhe Qiao; Yao Cheng; Shiyuan Liu; Zhenchuan Ma; Shaomin Li; Wei Zhang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-11-17       Impact factor: 3.000

Review 2.  Properties of flavonoids in the treatment of bladder cancer (Review).

Authors:  Yue Lv; Zhonghao Liu; Haixing Jia; Youcheng Xiu; Zan Liu; Leihong Deng
Journal:  Exp Ther Med       Date:  2022-09-19       Impact factor: 2.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.